Search clinical trials for: CC-90003

Total 859 results

Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Terminated

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Canada, Norway, Spain, United Kingdom
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Pulmonary Fibrosis

United States, Australia
Celgene

Completed

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

Healthy Volunteer

United States
Celgene

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Terminated

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Pathologic Processes | Fibrosis | Respiratory Tract Diseases | Lung Diseases | Idiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias

United States, Australia, Colombia, United Kingdom, Russian Federation, Brazil, Germany, Canada, Greece, Romania, Taiwan, Turkey, Ukraine
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Psoriasis

United States, Canada
Celgene Corporation

Completed

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Healthy Volunteers

United States
Celgene

Terminated

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Healthy Volunteers | Parapsoriasis

United States
Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Celgene

No longer available

Expanded Access for AG-221

Acute Myeloid Leukemia

United States
Celgene

Terminated

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Liver Cirrhosis | Non-alcoholic Fatty Liver Disease

United States, Spain, Australia, Korea, Republic of, Canada, Germany, France, Japan, United Kingdom, Poland
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Roswell Park Cancer Institute
Celgene

Withdrawn

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level

United States
Celgene

Completed

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Hematologic Neoplasms

Spain, United States
Celgene
AbbVie

Active, not recruiting

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, Canada, France, United Kingdom, Belgium
BTL Industries Ltd.

Completed

BTL-9000 Low Level Laser Therapy for the Waist Circumferential Reduction

Circumferential Reduction | Waist Circumferential Reduction
BTL Industries Ltd.

Completed

BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction

Circumferential Reduction | Waist Circumferential Reduction

Slovakia
Xuanwu Hospital, Beijing
Danyang Huichuang Medical Equipment Co., Ltd.

Recruiting

Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease

Alzheimer Disease

China
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Limb Girdle Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Active, not recruiting

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

Limb-Girdle Muscular Dystrophy, Type 2E

United States
Radboud University Medical Center
Norgine

Unknown

Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial (EXCEED)

Colorectal Neoplasms

Netherlands, Greece
Vitatron France

Unknown

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Sick Sinus Syndrome | Brady-Tachy Syndrome

France
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Johannes Kepler University of Linz

Recruiting

Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography

Macular Degeneration | Diabetic Retinopathy | Retinal Disease

Austria
King's College Hospital NHS Trust

Completed

Randomized Study of Pessary Versus Standard Management in Women With Increased Chance of Premature Birth

Preterm Birth

United Kingdom, Hong Kong, Chile, Spain, Slovenia, Colombia, Austria, Brazil, Germany, India, Italy, Portugal
Neurotrigger Ltd

Recruiting

Evaluate the Usability of the Neuro-trigger Artificial Eye Blinking Stimulation Device in Patients With Paralysis of the Facial Nerve. (paralysis)

Paralysis | Paralysis; Eye | Paralysis; Bell

Israel
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Celgene

Completed

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Infertility

Belgium
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study (CC-Test)

Pregnancy

Belgium
National Cancer Institute (NCI)

Completed

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Brain and Central Nervous System Tumors

United States
Boston Medical Center

Completed

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
VA Office of Research and Development

Not yet recruiting

Home-based Conservative Care Model for Advanced Kidney Disease

Chronic Kidney Diseases

United States

3

Subscribe